AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
FDA Meeting for ImmunityBio's Anktiva Drug Scuttled Amid Internal Opposition and Political Pressure
ByAinvest
Wednesday, Dec 3, 2025 6:15 am ET1min read
FDA scrapped a meeting about ImmunityBio's Anktiva drug, which was invited to by Republican lawmakers Ron Johnson and Neal Dunn. The meeting was intended to discuss the drug's potential expanded approval. Johnson said FDA officials opposed the lawmakers' attendance, citing concerns about political interference in the review process. An FDA spokesperson said the agency is committed to keeping the drug review process independent and free from outside influence.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet